HLB is taking control of changes of the future in various business fields, with
constant efforts and passion.
HLB speeding up to a Bio Group companies..expects the value of the Life Liver up.
Life Liver cooperates Promethera, Belgian Bio firm making human bio artificial liver
HLB is speeding up for changing into a bio specialized group with the help of subsidiaries.
It is focusing on Life Liver’s competency, which is in the artificial liver’s clinical trial, continuing to previous case with LSK Biopartners(LSK) which is producing targeted cancer medicine.
On Oct 31st, Life Liver announced that the company has contracted an equity investment agreement for cooperation development on human bio artificial liver & liver stem cell treatment, with a Belgian bio firm, Promethera Bioscience SA (Promethera). The investment amount is totally Eur 200million.
In this investment, Mitsubishi UFJ Capital, Cell Innovations Partners and Boehringer Ingelheim venture fund participated with Life Liver.
Promethera is a cell treatment specialized firm holding a core technique in stem cell originated from human liver. It secured stable stem cell supplying source, buying an US’ hepatocyte transplantation treatment development company named Cytonet.
Life Liver and Premethera starts developing treatments for human bio artificial liver & Nonalcoholic steatohepatitis (NASH). Life Liver has been developing bio artificial liver using gnotobiotic pigs, and now planning to use human liver cells to develop ‘Human Bio artificial liver’ for lower side effects. And also, will start Nonalcoholic steatohepatitis (NASH) clinical trial in Europe phase 2.
Life Liver said, “the investment and development cooperation this time indicates that the company has been recognized with its technological prowess in the bio artificial liver since 2001, from the global bio firms and bio funds”.
As HLB is equipped with targeted cancer medicine APATINIB, BTK inhibitor & surgical hemostat through LSKB, and artificial liver & NASH cell treatment through Life Liver, the securities business circles is expecting revaluation of HLB’s company value.